Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute Invite Applications for 2018 ADDF-Harrington Scholar Award

Up to $600,000 in Funding and Individualized Drug Development Support Available

Cleveland, Ohio – Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or cure people with Alzheimer’s disease, related dementias and cognitive-decline associated with aging.

Applicants have the opportunity to receive:

- Financial support up to $600,000 over two years
- Drug development and project management support through Harrington Discovery Institute’s Innovation Support Center

Collaborating for a cure:

“This is a tremendous opportunity for innovative researchers who seek a cure for Alzheimer’s and other dementias,” said Jonathan Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The ADDF-Harrington Scholar Award offers a unique combination of drug development expertise and funding to accelerate the most promising discoveries in Alzheimers disease into medicines.”

“Developing a drug for Alzheimer’s takes significant resources—in terms of both expertise and costs. This partnership was created to give researchers access to more of those resources so they can develop better drugs more rapidly. It has been very successful, and we are excited to continue the partnership,” noted Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF.

Award criteria:

- The competition is open to academic investigators at accredited medical centers, research institutions and universities in the United States;
- Lead investigator must have an MD and/or PhD or equivalent;
- Proposals should offer creative science or approach to treat, prevent or slow Alzheimer’s disease, other dementias or cognitive-decline associated with aging.

Please note the following dates:

- Letters of Intent will be accepted through May 25, 2018, 11:59 PM EDT
- Up to 3 awards will be announced by the end of December
- Applications must be submitted online at AlzDiscovery.org/RFPs

For more information, please visit HarringtonDiscovery.org/ADDF or AlzDiscovery.org.

Media contacts:
Alzheimer’s Drug Discovery Foundation
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded over $100 million to fund more than 500 Alzheimer’s drug discovery programs and clinical trials in 18 countries. To learn more, please visit: http://www.alzdiscovery.org/.

Harrington Discovery Institute
The Harrington Discovery Institute at University Hospitals in Cleveland, OH – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.

The Harrington Project for Discovery & Development
The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines.

For more information about The Harrington Project and the Harrington Discovery Institute, visit: HarringtonDiscovery.org.

University Hospitals
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals, more than 40 outpatient health centers and 200 physician offices in 15 counties throughout northern Ohio. The system’s flagship academic medical center, University Hospitals Cleveland Medical Center, located on a 35-acre campus in Cleveland’s University Circle, is affiliated with Case Western Reserve University School of Medicine. The main campus also includes University Hospitals Rainbow Babies & Children’s Hospital, ranked among the top children’s hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, including cancer, pediatrics, women's health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development. UH is one of the largest employers in Northeast Ohio with 26,000 employees.

UH’s vision is “Advancing the science of health and the art of compassion,” and its mission: “To Heal. To Teach. To Discover.” Follow UH on Facebook @UniversityHospitals and Twitter @UHhospitals. For more information, go to UHhospitals.org.